Amaryl, Avaglim(glimepiride)
Amaryl, Avaglim, Avandaryl, Duetact, Glimepiride, Tandemact (glimepiride) is a small molecule pharmaceutical. Glimepiride was first approved as Amaryl on 1995-11-30. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nutritional and metabolic diseases | D009750 |
| endocrine system diseases | D004700 |
Trade Name
FDA
EMA
Amaryl, Glimepiride (discontinued: Glimepiride)
CombinationsDuetact, Pioglitazone glimepiride (discontinued: Avandaryl, Rosiglitazone glimepiride)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Glimepiride
+
Pioglitazone hydrochloride
Glimepiride
+
Rosiglitazone maleate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| AVANDARYL | SB Pharmco | N-021700 DISCN | 2005-11-23 | 5 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| duetact | New Drug Application | 2022-10-24 |
| glimepiride | ANDA | 2024-10-25 |
| glimepiride 3 mg | ANDA | 2024-08-20 |
| pioglitazone and glimepiride | NDA authorized generic | 2021-12-16 |
| pioglitazone hydrochloride and glimepiride | ANDA | 2018-06-18 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| type 2 diabetes mellitus | EFO_0001360 | D003924 | E11 |
Agency Specific
FDA
EMA
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BB: Sulfonylureas for blood glucose lowering
— A10BB12: Glimepiride
— A10BD: Combinations of oral blood glucose lowering drugs
— A10BD04: Glimepiride and rosiglitazone
— A10BD06: Glimepiride and pioglitazone
HCPCS
No data
Clinical
Clinical Trials
269 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 8 | 13 | 94 | 72 | 35 | 219 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 4 | 13 | 85 | 49 | 21 | 169 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | 1 | 3 | 5 | 9 |
| Hypoglycemia | D007003 | HP_0001943 | E16.2 | 1 | — | — | 2 | 1 | 4 |
| Coronary disease | D003327 | — | — | — | — | 1 | 1 | 1 | 3 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | 1 | 1 | — | 2 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | — | 1 | 1 | 2 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | 1 | 1 | 2 |
| Albuminuria | D000419 | EFO_0004285 | R80.9 | — | — | — | 2 | — | 2 |
| Insulin resistance | D007333 | HP_0000855 | — | — | — | — | 2 | — | 2 |
Show 11 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | 1 | — | 1 | 2 |
| Hypercholesterolemia | D006937 | HP_0003124 | — | — | — | 1 | — | — | 1 |
| Dyslipidemias | D050171 | HP_0003119 | — | — | — | 1 | — | — | 1 |
| Peripheral nervous system diseases | D010523 | HP_0009830 | G64 | — | 1 | 1 | — | — | 1 |
| Diabetic neuropathies | D003929 | EFO_1000783 | — | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | HP_0001635 | I50 | — | 1 | — | — | 3 | 4 |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | 1 | — | — | 1 | 2 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 16 | — | — | — | 3 | 19 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 1 | — | — | — | 1 | 2 |
| Disease | D004194 | EFO_0000408 | R69 | 1 | — | — | — | — | 1 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatitis | D010195 | HP_0001733 | K85 | — | — | — | — | 1 | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | — | — | — | 1 | 1 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | — | — | — | — | 1 | 1 |
| Neoplasms | D009369 | — | C80 | — | — | — | — | 1 | 1 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | — | 1 | 1 |
| Glucose metabolism disorders | D044882 | — | — | — | — | — | — | 1 | 1 |
| Cohort studies | D015331 | — | — | — | — | — | — | 1 | 1 |
| Recreational drug use | D000084783 | — | — | — | — | — | — | 1 | 1 |
| Retinal diseases | D012164 | HP_0000479 | H35.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Glimepiride |
| INN | glimepiride |
| Description | Glimepiride is a sulfonamide, a N-acylurea and a N-sulfonylurea. It has a role as a hypoglycemic agent and an insulin secretagogue. |
| Classification | Small molecule |
| Drug class | antidiabetics |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O |
Identifiers
| PDB | — |
| CAS-ID | 93479-97-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1481 |
| ChEBI ID | 5383 |
| PubChem CID | 3476 |
| DrugBank | DB00222 |
| UNII ID | 6KY687524K (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Glimepiride
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Glimepiride
+
Pioglitazone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Glimepiride
+
Rosiglitazone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 8,081 documents
View more details
Safety
Black-box Warning
Black-box warning for: Duetact, Pioglitazone and glimepiride, Pioglitazone hydrochloride and glimepiride
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
11,836 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use